TAp73α increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation(420 views) Malaguarnera R, Vella V, Pandini G, Sanfilippo M, Pezzino V, Vigneri R, Frasca F
Mol Cancer Res (ISSN: 1541-7786), 2008; 6(1): 64-77.
Keywords: Mutant Protein, Protein Mdm2, Protein P53, Protein Tap73alpha, Small Interfering Rna, Unclassified Drug, Article, Binding Site, Cancer Cell, Cancer Inhibition, Controlled Study, Dna Binding, Gene Deletion, Human, Human Cell, Priority Journal, Protein Binding, Protein Degradation, Protein Expression, Protein Function, Protein Protein Interaction, Protein Stability, Thyroid Cancer, Bcl-2-Associated X Protein, Competitive, Cell Line, Tumor, Cyclin-Dependent Kinase Inhibitor P21, Dna-Binding Proteins, Gene Expression Regulation, Neoplastic, Nuclear Proteins, Promoter Regions (genetics), Protein Processing, Post-Translational, Proto-Oncogene Proteins C-Mdm2, Thermodynamics, Thyroid Neoplasms, Transcription, Tumor Suppressor Protein P53,
Affiliations: *** IBB - CNR ***
Endocrinologia-Dipartimento di Medicina Interna e di Medicina Specialistica-Universita di Catania, Ospedale Garibaldi, Nesima, Italy
Serv. di Diabetologia-Dipto. di Medicina Interna e di Medicina Specialistica-Universita di Catania, Ospedale Cannizzaro, Catania, Italy
References: Murray-Zmijewski, F., Lane, D.P., Bourdon, J.C., p53/p63/p73 isoforms: An orchestra of isoforms to harmonise cell differentiation and response to stress (2006) Cell Death Differ, 13, pp. 962-97
Moll, U.M., Slade, N., p63 and p73: Roles in development and tumor formation (2004) Mol Cancer Res, 2, pp. 371-386
Blandino, G., Dobbelstein, M., p73 and p63: Why do we still need them? (2004) Cell Cycle, 3, pp. 886-894
Moll, U.M., Erster, S., Zaika, A., p53, p63 and p73 - solos, alliances and feuds among family members (2001) Biochim Biophys Acta, 1552, pp. 47-59
Ghosh, A., Stewart, D., Matlashewski, G., Regulation of human p53 activity and cell localization by alternative splicing (2004) Mol Cell Biol, 24, pp. 7987-7997
Bourdon, J.C., Fernandes, K., Murray-Zmijewski, F., p53 isoforms can regulate p53 transcriptional activity (2005) Genes Dev, 19, pp. 2122-2137
Courtois, S., de Fromentel, C.C., Hainaut, P., p53 protein variants: Structural and functional similarities with p63 and p73 isoforms (2004) Oncogene, 23, pp. 631-638
Mills AA. p53: link to the past, bridge to the future. Genes Dev 2005
19:2091-9Rohaly, G., Chemnitz, J., Dehde, S., A novel human p53 isoform is an essential element of the ATR-intra-S phase checkpoint (2005) Cell, 122, pp. 21-32
Harms, K., Nozell, S., Chen, X., The common and distinct target genes of the p53 family transcription factors (2004) Cell Mol Life Sci, 61, pp. 822-842
Benard, J., Douc-Rasy, S., Ahomadegbe, J.C., TP53 family members and human cancers (2003) Hum Mutat, 21, pp. 182-191
Irwin, M.S., Kaelin, W.G., p53 family update: P73 and p63 develop their own identities (2001) Cell Growth Differ, 12, pp. 337-349
Marin, M.C., Kaelin Jr, W.G., p63 and p73: Old members of a new family (2000) Biochim Biophys Acta, 1470, pp. M93-100
Harms, K.L., Chen, X., The C terminus of p53 family proteins is a cell fate determinant (2005) Mol Cell Biol, 25, pp. 2014-2030
Kim, E.J., Park, J.S., Um, S.J., Identification and characterization of HIPK2 interacting with p73 and modulating functions of the p53 family in vivo (2002) J Biol Chem, 277, pp. 32020-32028
Lohrum, M.A., Vousden, K.H., Regulation and function of the p53-related proteins: Same family, different rules (2000) Trends Cell Biol, 10, pp. 197-202
Save, V., Nylander, K., Hall, P.A., Why is p53 protein stabilized in neoplasia? Some answers but many more questions? (1998) J Pathol, 184, pp. 348-350
Mills, A.A., Zheng, B., Wang, X.J., Vogel, H., Roop, D.R., Bradley, A., p63 is a p53 homologue required for limb and epidermal morphogenesis (1999) Nature, 398, pp. 708-713
Yang, A., Walker, N., Bronson, R., p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours (2000) Nature, 404, pp. 99-103
Pozniak, C.D., Radinovic, S., Yang, A., McKeon, F., Kaplan, D.R., Miller, F.D., An anti-apoptotic role for the p53 family member, p73, during developmental neuron death (2000) Science, 289, pp. 304-306
Pilozzi, E., Talerico, C., Platt, A., Fidler, C., Ruco, L., p73 gene mutations in gastric adenocarcinomas (2003) Mol Pathol, 56, pp. 60-62
Akahoshi, K., Sakazume, S., Kosaki, K., Ohashi, H., Fukushima, Y., EEC syndrome type 3 with a heterozygous germline mutation in the P63 gene and B cell lymphoma (2003) Am J Med Genet A, 120, pp. 370-373
Olivier, M., Eeles, R., Hollstein, M., Khan, M.A., Harris, C.C., Hainaut, P., The IARC TP53 database: Newonline mutation analysis and recommendations to users (2002) Hum Mutat, 19, pp. 607-614
Moll UM. The Role of p63 and p73 in tumor formation and progression: coming of age toward clinical usefulness. Commentary re: F. Koga et al., Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder [Clin Cancer Res 2003
9:5501-7] and Puig P, et al. p73 Expression in human normal and tumor tissues: loss of p73α expression is associated with tumor progression in bladder [Clin Cancer Res 2003
9:5642-51]. Clin Cancer Res 2000
9:5437-41Park, B.J., Lee, S.J., Kim, J.I., Frequent alteration of p63 expression in human primary bladder carcinomas (2000) Cancer Res, 60, pp. 3370-3374
Di Como, C.J., Urist, M.J., Babayan, I., p63 expression profiles in human normal and tumor tissues (2002) Clin Cancer Res, 8, pp. 494-501
Concin, N., Hofstetter, G., Berger, A., Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: Evidence for a crucial p53-73 cross-talk in vivo (2005) Clin Cancer Res, 11, pp. 8372-8383
Guan, M., Chen, Y., Aberrant expression of ΔNp73 in benign and malignant tumours of the prostate: Correlation with Gleason score (2005) J Clin Pathol, 58, pp. 1175-1179
Muller, M., Schilling, T., Sayan, A.E., TAp73/ΔNp73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma (2005) Cell Death Differ, 12, pp. 1564-1577
Ugur, H., Sayan, A.E., Ozdamar, S.O., Kanpolat, Y., Ozturk, M., Expression of TAP73 and ΔNP73 in malignant gliomas (2004) Oncol Rep, 11, pp. 1337-1341
Concin, N., Becker, K., Slade, N., Transdominant ΔTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo (2004) Cancer Res, 64, pp. 2449-2460
Casciano, I., Mazzocco, K., Boni, L., Expression of ΔNp73 is a molecular marker for adverse outcome in neuroblastoma patients (2002) Cell Death Differ, 9, pp. 246-251
Flores, E.R., Tsai, K.Y., Crowley, D., p63 and p73 are required for p53-dependent apoptosis in response to DNA damage (2002) Nature, 416, pp. 560-564
Flores, E.R., Sengupta, S., Miller, J.B., Tumor predisposition in mice mutant for p63 and p73: Evidence for broader tumor suppressor functions for the p53 family (2005) Cancer Cell, 7, pp. 363-373
Vikhanskaya, F., D'Incalci, M., Broggini, M., p73 competes with p53 and attenuates its response in a human ovarian cancer cell line (2000) Nucleic Acids Res, 28, pp. 513-519
Koster, M.I., Lu, S.L., White, L.D., Wang, X.J., Roop, D.R., Reactivation of developmentally expressed p63 isoforms predisposes to tumor development and progression (2006) Cancer Res, 66, pp. 3981-3986
Malaguarnera, R., Mandarino, A., Mazzon, E., The p53-homologue p63 may promote thyroid cancer progression (2005) Endocr Relat Cancer, 12, pp. 953-971
Frasca, F., Vella, V., Aloisi, A., p73 tumor-suppressor activity is impaired in human thyroid cancer (2003) Cancer Res, 63, pp. 5829-5837
Ito, Y., Uramoto, H., Funa, K., ΔNp73 expression in thyroid neoplasms originating from follicular cells (2006) Pathology, 38, pp. 205-209
Preto, A., Reis-Filho, J.S., Ricardo, S., Soares, P., P63 expression in papillary and anaplastic carcinomas of the thyroid gland: Lack of an oncogenetic role in tumorigenesis and progression (2002) Pathol Res Pract, 198, pp. 449-454
Reis-Filho, J.S., Preto, A., Soares, P., Ricardo, S., Cameselle-Teijeiro, J., Sobrinho-Simoes, M., p63 expression in solid cell nests of the thyroid: Further evidence for a stem cell origin (2003) Mod Pathol, 16, pp. 43-48
Unger, P., Ewart, M., Wang, B.Y., Gan, L., Kohtz, D.S., Burstein, D.E., Expression of p63 in papillary thyroid carcinoma and in Hashimoto's thyroiditis: A pathobiologic link? (2003) Hum Pathol, 34, pp. 764-769
Hunt, J.L., LiVolsi, V.A., Barnes, E.L., p63 expression in sclerosing mucoepidermoid carcinomas with eosinophilia arising in the thyroid (2004) Mod Pathol, 17, pp. 526-529
Burstein, D.E., Nagi, C., Wang, B.Y., Unger, P., Immunohistochemical detection of p53 homolog p63 in solid cell nests, papillary thyroid carcinoma, and Hashimoto's thyroiditis: A stem cell hypothesis of papillary carcinoma oncogenesis (2004) Hum Pathol, 35, pp. 465-473
Ferru, A., Denis, S., Guilhot, J., Expression of TAp73 and ΔNp73 isoform transcripts in thyroid tumours (2006) Eur J Surg Oncol, 32, pp. 228-230
Fagin, J.A., Matsuo, K., Karmakar, A., Chen, D.L., Tang, S.H., Koeffler, H.P., High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas (1993) J Clin Invest, 91, pp. 179-184
Moretti, F., Farsetti, A., Soddu, S., p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells (1997) Oncogene, 14, pp. 729-740
Blagosklonny, M.V., Giannakakou, P., Wojtowicz, M., Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells (1998) J Clin Endocrinol Metab, 83, pp. 2516-2522
Narimatsu, M., Nagayama, Y., Akino, K., Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line (1998) J Clin Endocrinol Metab, 83, pp. 3668-3672
Nagayama, Y., Yokoi, H., Takeda, K., Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo (2000) J Clin Endocrinol Metab, 85, pp. 4081-4086
Imanishi, R., Ohtsuru, A., Iwamatsu, M., A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy (2002) J Clin Endocrinol Metab, 87, pp. 4821-4824
Podtcheko, A., Ohtsuru, A., Tsuda, S., The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells (2003) J Clin Endocrinol Metab, 88, pp. 1889-1896
Wu, X., Bayle, J.H., Olson, D., Levine, A.J., The p53-mdm-2 autoregulatory feedback loop (1993) Genes Dev, 7, pp. 1126-1132
Balint, E., Bates, S., Vousden, K.H., Mdm2 binds p73α without targeting degradation (1999) Oncogene, 18, pp. 3923-3929
Huqun, Endo, Y., Xin, H., Takahashi, M., Nukiwa, T., Hagiwara, K., A naturally occurring p73 mutation in a p73-53 double-mutant lung cancer cell line encodes p73 α protein with a dominant-negative function (2003) Cancer Sci, 94, pp. 718-724
Miro-Mur, F., Meiller, A., Haddada, H., May, E., p73α expression induces both accumulation and activation of wt-p53 independent of the p73α transcriptional activity (2003) Oncogene, 22, pp. 5451-5456
Senoo, M., Manis, J.P., Alt, F.W., McKeon, F., p63 and p73 are not required for the development and p53-dependent apoptosis of T cells (2004) Cancer Cell, 6, pp. 85-89
Vikhanskaya, F., Marchini, S., Marabese, M., Galliera, E., Broggini, M., P73a overexpression is associated with resistance to treatment with DNA-damaging agents in a human ovarian cancer cell line (2001) Cancer Res, 61, pp. 935-938
Freebern, W.J., Smith, J.L., Chaudhry, S.S., Haggerty, C.M., Gardner, K., Novel cell-specific and dominant negative anti-apoptotic roles of p73 in transformed leukemia cells (2003) J Biol Chem, 278, pp. 2249-2255
De Laurenzi, V., Costanzo, A., Barcaroli, D., Two new p73 splice variants, γ and δ, with different transcriptional activity (1998) J Exp Med, 188, pp. 1763-1768
Strano, S., Munarriz, E., Rossi, M., Physical interaction with Yes-associated protein enhances p73 transcriptional activity (2001) J Biol Chem, 276, pp. 15164-15173
Thanos, C.D., Bowie, J.U., p53 Family members p63 and p73 are SAM domain containing proteins (1999) Protein Sci, 8, pp. 1708-1710
Gu, J., Nie, L., Kawai, H., Yuan, Z.M., Subcellular distribution of p53 and p73 are differentially regulated by MDM2 (2001) Cancer Res, 61, pp. 6703-6707
Grob, T.J., Novak, U., Maisse, C., Human δ Np73 regulates a dominant negative feedback loop for TAp73 and p53 (2001) Cell Death Differ, 8, pp. 1213-1223
Chi, S.W., Ayed, A., Arrowsmith, C.H., Solution structure of a conserved C-terminal domain of p73 with structural homology to the SAM domain (1999) EMBO J, 18, pp. 4438-4445
Davison, T.S., Vagner, C., Kaghad, M., Ayed, A., Caput, D., Arrowsmith, C.H., p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53 (1999) J Biol Chem, 274, pp. 18709-18714
Zeimet, A.G., Marth, C., Why did p53 gene therapy fail in ovarian cancer? (2003) Lancet Oncol, 4, pp. 415-422
Moll, U. M., Slade, N., p63 and p73: Roles in development and tumor formation (2004) Mol Cancer Res, 2, pp. 371-386
Moll, U. M., Erster, S., Zaika, A., p53, p63 and p73 - solos, alliances and feuds among family members (2001) Biochim Biophys Acta, 1552, pp. 47-59
Bourdon, J. C., Fernandes, K., Murray-Zmijewski, F., p53 isoforms can regulate p53 transcriptional activity (2005) Genes Dev, 19, pp. 2122-2137
19: 2091-9Rohaly, G., Chemnitz, J., Dehde, S., A novel human p53 isoform is an essential element of the ATR-intra-S phase checkpoint (2005) Cell, 122, pp. 21-32
Irwin, M. S., Kaelin, W. G., p53 family update: P73 and p63 develop their own identities (2001) Cell Growth Differ, 12, pp. 337-349
Marin, M. C., Kaelin Jr, W. G., p63 and p73: Old members of a new family (2000) Biochim Biophys Acta, 1470, pp. M93-100
Harms, K. L., Chen, X., The C terminus of p53 family proteins is a cell fate determinant (2005) Mol Cell Biol, 25, pp. 2014-2030
Kim, E. J., Park, J. S., Um, S. J., Identification and characterization of HIPK2 interacting with p73 and modulating functions of the p53 family in vivo (2002) J Biol Chem, 277, pp. 32020-32028
Lohrum, M. A., Vousden, K. H., Regulation and function of the p53-related proteins: Same family, different rules (2000) Trends Cell Biol, 10, pp. 197-202
Mills, A. A., Zheng, B., Wang, X. J., Vogel, H., Roop, D. R., Bradley, A., p63 is a p53 homologue required for limb and epidermal morphogenesis (1999) Nature, 398, pp. 708-713
Pozniak, C. D., Radinovic, S., Yang, A., McKeon, F., Kaplan, D. R., Miller, F. D., An anti-apoptotic role for the p53 family member, p73, during developmental neuron death (2000) Science, 289, pp. 304-306
9: 5501-7] and Puig P, et al. p73 Expression in human normal and tumor tissues: loss of p73 expression is associated with tumor progression in bladder [Clin Cancer Res 2003
9: 5642-51]. Clin Cancer Res 2000
9: 5437-41Park, B. J., Lee, S. J., Kim, J. I., Frequent alteration of p63 expression in human primary bladder carcinomas (2000) Cancer Res, 60, pp. 3370-3374
Di Como, C. J., Urist, M. J., Babayan, I., p63 expression profiles in human normal and tumor tissues (2002) Clin Cancer Res, 8, pp. 494-501
Flores, E. R., Tsai, K. Y., Crowley, D., p63 and p73 are required for p53-dependent apoptosis in response to DNA damage (2002) Nature, 416, pp. 560-564
Flores, E. R., Sengupta, S., Miller, J. B., Tumor predisposition in mice mutant for p63 and p73: Evidence for broader tumor suppressor functions for the p53 family (2005) Cancer Cell, 7, pp. 363-373
Koster, M. I., Lu, S. L., White, L. D., Wang, X. J., Roop, D. R., Reactivation of developmentally expressed p63 isoforms predisposes to tumor development and progression (2006) Cancer Res, 66, pp. 3981-3986
Reis-Filho, J. S., Preto, A., Soares, P., Ricardo, S., Cameselle-Teijeiro, J., Sobrinho-Simoes, M., p63 expression in solid cell nests of the thyroid: Further evidence for a stem cell origin (2003) Mod Pathol, 16, pp. 43-48
Hunt, J. L., LiVolsi, V. A., Barnes, E. L., p63 expression in sclerosing mucoepidermoid carcinomas with eosinophilia arising in the thyroid (2004) Mod Pathol, 17, pp. 526-529
Burstein, D. E., Nagi, C., Wang, B. Y., Unger, P., Immunohistochemical detection of p53 homolog p63 in solid cell nests, papillary thyroid carcinoma, and Hashimoto's thyroiditis: A stem cell hypothesis of papillary carcinoma oncogenesis (2004) Hum Pathol, 35, pp. 465-473
Fagin, J. A., Matsuo, K., Karmakar, A., Chen, D. L., Tang, S. H., Koeffler, H. P., High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas (1993) J Clin Invest, 91, pp. 179-184
Blagosklonny, M. V., Giannakakou, P., Wojtowicz, M., Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells (1998) J Clin Endocrinol Metab, 83, pp. 2516-2522
Wu, X., Bayle, J. H., Olson, D., Levine, A. J., The p53-mdm-2 autoregulatory feedback loop (1993) Genes Dev, 7, pp. 1126-1132
Freebern, W. J., Smith, J. L., Chaudhry, S. S., Haggerty, C. M., Gardner, K., Novel cell-specific and dominant negative anti-apoptotic roles of p73 in transformed leukemia cells (2003) J Biol Chem, 278, pp. 2249-2255
Thanos, C. D., Bowie, J. U., p53 Family members p63 and p73 are SAM domain containing proteins (1999) Protein Sci, 8, pp. 1708-1710
Grob, T. J., Novak, U., Maisse, C., Human Np73 regulates a dominant negative feedback loop for TAp73 and p53 (2001) Cell Death Differ, 8, pp. 1213-1223
Chi, S. W., Ayed, A., Arrowsmith, C. H., Solution structure of a conserved C-terminal domain of p73 with structural homology to the SAM domain (1999) EMBO J, 18, pp. 4438-4445
Davison, T. S., Vagner, C., Kaghad, M., Ayed, A., Caput, D., Arrowsmith, C. H., p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53 (1999) J Biol Chem, 274, pp. 18709-18714
Zeimet, A. G., Marth, C., Why did p53 gene therapy fail in ovarian cancer? (2003) Lancet Oncol, 4, pp. 415-422
TAp73α increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation